What ridiculousness are the stock promoting shills for everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), spewing in this holiday-shortened, and retail trader dominated week? Today it is some epic nonsense about a supposed Nasdaq “uplisting.” Say the shills:

The $4 level is referring to the Nasdaq’s $4 Minimum Bid Price requirement. The problem is that, barring epic improvements in Cytodyn’s financial situation by the time the current (February-ending) quarter ends, the company must meet the $4 minimum bid price test for 90 days, not 5. Which will require another 85 consecutive days of trading above the $4 requirement. Just look up the requirements for yourself at the Nasdaq’s website where you will find out that:

Want to learn more about the initial listing requirements for Nasdaq? Read about them here, here and here. Of course Cytodyn management knows about the requirements, and knows the company does not qualify, but they keep up the hype regardless. In the lawsuit that they do not want investors to ever read are these nuggets from Paragraph 38:

And Paragraph 105:

Yet The NaDDir*, his Klown Krew and the CYDY stock promoters continued to make false promises of a Nasdaq listing throughout 2020.

Keen readers will probably be asking themselves, based on Cytodyn’s pattern-to-date, “if the company is trying to get investors to look at the dream of a Nasdaq listing, what are they trying to get investors to ignore? There must be something.” And there is.

Most likely the latest barrage of stock promoting, false listing nonsense is to distract from the Form 144 filing that recently came out, in which David Welch, former board member and Cytodyn’s largest shareholder, continues to sell stock. Haven’t seen it yet? Consider this a little Christmas gift from the curmudgeons at BuyersStrike! HQ to you.

He sold stock in October too:

And in November:

And continuing into late November and early December:

Clearly a huge vote of confidence in The NaDDir* and loserlimab!

[Did you know Cytodyn is being sued by a group of former directors? What to know why? See here and here.]

[Did you know Loserlimab has virtually no chance of ever getting an EUA in the United States? Want to know why? See here.]

* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.